Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GFH276 with tislelizumab, pemetrexed, and platinum as first-line treatment for RAS-mutant advanced non-squamous non-small cell lung cancer
CTR20263962Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH276 in non-small cell lung cancer (NSCLC), sponsored by GenFleet Therapeutics. Started Oct 2026; status: active.
02
Drugs
GFH276
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263962.